Patents Assigned to A2 Biotherapeutics, Inc.
  • LILRB1-based chimeric antigen receptor
    Patent number: 12037377
    Abstract: Provided are chimeric antigen receptors having the hinge, transmembrane region, and/or intracellular domain of LILRB1, or functional fragments or variants thereof. Also provided herein are cells comprising the LILRB1 based receptors, and methods of making and using same.
    Type: Grant
    Filed: May 12, 2022
    Date of Patent: July 16, 2024
    Assignee: A2 BIOTHERAPEUTICS, INC.
    Inventors: Carl Alexander Kamb, Agnes E. Hamburger, Breanna Diandreth, Mark E. Daris, Kiran Deshmukh
  • Engineered immune cells with receptor signal strength modulated by a hinge
    Patent number: 12012612
    Abstract: The present disclosure provides engineered immune cells and methods for their creation and use. The immune cells comprise activating and blocking receptors. The signals of the activating and blocking receptors can be modulated via the identity of a hinge.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: June 18, 2024
    Assignee: A2 BIOTHERAPEUTICS, INC.
    Inventor: Alexander Kamb
  • Engineered immune cells with receptor cross-talk
    Patent number: 11976297
    Abstract: The present disclosure provides engineered immune cells and methods for their creation and use. The immune cells comprise activating and blocking receptors, that exhibit cross-talk between the receptors.
    Type: Grant
    Filed: September 21, 2021
    Date of Patent: May 7, 2024
    Assignee: A2 BIOTHERAPEUTICS, INC.
    Inventor: Alexander Kamb
  • Compositions and methods for treating HER2 positive cancers
    Patent number: 11730764
    Abstract: The disclosure relates to immune cells comprising a dual receptor system responsive to loss of heterozygosity in a target cell, and methods of making and using same. The first receptor comprises activator receptor specific to a HER2 antigen, and the second receptor comprises an inhibitory receptor specific to an antigen lost in cancer but not wild type cells, that inhibits activation of the immune cells by the first receptor.
    Type: Grant
    Filed: June 28, 2022
    Date of Patent: August 22, 2023
    Assignee: A2 Biotherapeutics, Inc.
    Inventors: Yuta Ando, Julyun Oh, Han Xu, Carl Alexander Kamb
  • Compositions and methods for treating mesothelin positive cancers
    Patent number: 11602543
    Abstract: The disclosure provides immune cells comprising a first activator receptor specific to mesothelin and a second inhibitory receptor specific to a ligand that has been lost in a mesothelin-positive cancer cell, and methods of making and using same for the treatment of cancer.
    Type: Grant
    Filed: May 10, 2022
    Date of Patent: March 14, 2023
    Assignee: A2 Biotherapeutics, Inc.
    Inventors: Carl Alexander Kamb, Dora Toledo Warshaviak, Talar Tokatlian, Agnes Hamburger
  • Compositions and methods for treating EGFR positive cancers
    Patent number: 11602544
    Abstract: The disclosure provides immune cells comprising a first activator receptor and a second inhibitory receptor, and methods of making and using same for the treatment of cancer.
    Type: Grant
    Filed: May 17, 2022
    Date of Patent: March 14, 2023
    Assignee: A2 Biotherapeutics, Inc.
    Inventors: Julyun Oh, Han Xu, Carl Alexander Kamb
  • Compositions and methods for treating ceacam positive cancers
    Patent number: 11433100
    Abstract: The disclosure provides immune cells comprising a first activator receptor specific to CEA, and a second inhibitory receptor, and methods of making and using same for the treatment of cancer.
    Type: Grant
    Filed: November 2, 2021
    Date of Patent: September 6, 2022
    Assignee: A2 Biotherapeutics, Inc.
    Inventors: Xueyin Wang, Carl Alexander Kamb, Han Xu, Mark L. Sandberg, Dora Toledo Warshaviak
  • LILRB1-based chimeric antigen receptor
    Patent number: 11254726
    Abstract: Provided are chimeric antigen receptors having the hinge, transmembrane region, and/or intracellular domain of LILRB1, or functional fragments or variants thereof. Also provided herein are cells comprising the LILRB1 based receptors, and methods of making and using same.
    Type: Grant
    Filed: April 14, 2021
    Date of Patent: February 22, 2022
    Assignee: A2 Biotherapeutics, Inc.
    Inventors: Carl Alexander Kamb, Agnes E. Hamburger, Breanna Diandreth, Mark E. Daris, Kiran Deshmukh